Lynx Therapeutics - LYNX- Profile

Lynx Therapeutics Incorporated. The Company develops novel technologies for the discovery of gene expression patterns and genomic variations important to the pharmaceutical, biotechnology and agricultural industries. These technologies are based on Megaclone, which transforms millions of DNA molecules into one made up of millions of micro beads. The principal collaborators and customers of the Group are BASF AG, E.I DuPont de Nemours and Company, Aventis Cropscience GmbH, and the Institute of Molecular and Cell Biology. The trade marks used are Megaclone, Mpss, Megasort, Megatype and Protein ProFiler.